CD8A and neoplasm: These results imply that Adam2 downregulates type I/II IFN and TNFα responses as well as MHC-I expression, while upregulating other key immune-modulatory receptors on tumor cells resulting in reduced cross-presentation of TAA to antigen-specific CD8 T cells.